{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:04:08Z","timestamp":1787753048182,"version":"build-2784847793"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/ogx.0000000000000036","type":"journal-article","created":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T12:27:32Z","timestamp":1392812852000},"page":"100-108","source":"Crossref","is-referenced-by-count":26,"title":["The Impact of Preoperative Gonadotropin-Releasing Hormone Agonist Treatment on Women With Uterine Fibroids"],"prefix":"10.1097","volume":"69","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinshu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiumei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210212","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0301-2115(99)00168-2","article-title":"Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial.","volume":"89","author":"Verspyck","year":"2000","journal-title":"Eur J Obstet Gyn R B"},{"key":"R2-16-20210212","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids.","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-16-20210212","first-page":"1424","article-title":"What are the implications of myomas on fertility A need for a debate Hum Reprod.","volume":"17","author":"Donnez","year":"2002","journal-title":""},{"key":"R4-16-20210212","first-page":"1","article-title":"Management of uterine fibroids: an update of the evidence.","volume":"154","author":"Viswanathan","year":"2007","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"R5-16-20210212","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1210\/jc.2008-2093","article-title":"Progestins activate the AKT pathway in leiomyoma cells and promote survival.","volume":"94","author":"Hoekstra","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-16-20210212","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/0008-5472.CAN-09-2612","article-title":"Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells.","volume":"70","author":"Yin","year":"2010","journal-title":"Cancer Res"},{"key":"R8-16-20210212","first-page":"20","article-title":"Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues.","volume":"55","author":"Wilson","year":"1980","journal-title":"Obstet Gynecol"},{"key":"R9-16-20210212","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/00016348509155136","article-title":"Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium.","volume":"64","author":"Tamaya","year":"1985","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R10-16-20210212","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2265.1994.tb02495.x","article-title":"Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women.","volume":"40","author":"Vollenhoven","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R11-16-20210212","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1471-0528.2002.01225.x","article-title":"Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review.","volume":"109","author":"Lethaby","year":"2002","journal-title":"BJOG"},{"key":"R12-16-20210212","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0029-7844(95)00102-W","article-title":"GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group.","volume":"86","author":"Stovall","year":"1995","journal-title":"Obstet Gynecol"},{"key":"R13-16-20210212","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/humrep\/deq188","article-title":"The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial.","volume":"25","author":"Mavrelos","year":"2010","journal-title":"Hum Reprod"},{"key":"R14-16-20210212","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/1468-2389.00156","article-title":"Fixed effects vs. random effects meta-analysis models: implications for cumulative research knowledge.","volume":"8","author":"Hunter","year":"2000","journal-title":"Int J Select Assess"},{"key":"R15-16-20210212","first-page":"1024","article-title":"Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes.","volume":"30","author":"Sayyah-Melli","year":"2009","journal-title":"Saudi Med J"},{"key":"R16-16-20210212","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.fertnstert.2009.05.070","article-title":"GnRH analogue treatment before hysteroscopic resection of submucous myomas: a prospective, randomized, multicenter study.","volume":"94","author":"Muzii","year":"2010","journal-title":"Fertil Steril"},{"key":"R17-16-20210212","first-page":"445","article-title":"Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and cabergoline (Dostinex) treatment on uterine myoma regression.","volume":"28","author":"Melli","year":"2007","journal-title":"Saudi Med J"},{"key":"R18-16-20210212","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejogrb.2006.07.042","article-title":"A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.","volume":"135","author":"Baytur","year":"2007","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R19-16-20210212","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0015-0282(03)00362-5","article-title":"Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial.","volume":"79","author":"Vercellini","year":"2003","journal-title":"Fertil Steril"},{"key":"R20-16-20210212","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0015-0282(03)00261-9","article-title":"A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy.","volume":"79","author":"Donnez","year":"2003","journal-title":"Fertil Steril"},{"key":"R21-16-20210212","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"R22-16-20210212","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"R24-16-20210212","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/humrep\/14.1.44","article-title":"Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues.","volume":"14","author":"Campo","year":"1999","journal-title":"Hum Reprod"},{"key":"R25-16-20210212","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/j.1471-0528.1998.tb09967.x","article-title":"Treatment with a gonadotrophin releasing hormone agonist before hysterectomy for leiomyomas: results of a multicentre, randomised controlled trial.","volume":"105","author":"Vercellini","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"issue":"suppl","key":"R26-16-20210212","first-page":"31","article-title":"Preoperative use of Zoladex for treatment of uterine fibromyomas.","volume":"76","author":"Nikolov","year":"1997","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R27-16-20210212","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0015-0282(16)58443-X","article-title":"Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study.","volume":"66","author":"Benagiano","year":"1996","journal-title":"Fertil Steril"},{"key":"R28-16-20210212","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000184806","article-title":"The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group.","volume":"45","author":"Gerris","year":"1996","journal-title":"Horm Res"},{"key":"R30-16-20210212","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3109\/00016349509024390","article-title":"Trial of routine gonadotropin releasing hormone agonist treatment before abdominal hysterectomy for leiomyoma.","volume":"74","author":"Balasch","year":"1995","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R31-16-20210212","first-page":"102","article-title":"Administration of preoperative gonadotropin releasing hormone agonist (buserelin) for uterine leiomyomas.","volume":"4","author":"Cetin","year":"1995","journal-title":"Ann Med Sci"},{"issue":"suppl 10","key":"R32-16-20210212","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1471-0528.1994.tb13683.x","article-title":"Deferred versus immediate surgery for uterine fibroids: clinical trial results.","volume":"101","author":"Audebert","year":"1994","journal-title":"Br J Obstet Gynaecol"},{"key":"R33-16-20210212","first-page":"263","article-title":"Role of goserelin-depot in the clinical management of uterine fibroids.","volume":"21","author":"Cagnacci","year":"1994","journal-title":"Clin Exp Obstet Gynecol"},{"key":"R34-16-20210212","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1471-0528.1994.tb11919.x","article-title":"Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids.","volume":"101","author":"Lumsden","year":"1994","journal-title":"Br J Obstet Gynaecol"},{"key":"R36-16-20210212","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/oxfordjournals.humrep.a138070","article-title":"Pre-operative gonadotrophin-releasing hormone agonist treatment in surgery for uterine leiomyomata.","volume":"8","author":"Golan","year":"1993","journal-title":"Hum Reprod"},{"key":"R37-16-20210212","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1471-0528.1990.tb01824.x","article-title":"Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence.","volume":"97","author":"Fedele","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"R38-16-20210212","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0015-0282(16)61022-1","article-title":"A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy.","volume":"52","author":"Friedman","year":"1989","journal-title":"Fertil Steril"},{"issue":"suppl 1","key":"R39-16-20210212","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000181332","article-title":"Mechanism of LHRH analogue action in uterine fibroids.","volume":"32","author":"Shaw","year":"1989","journal-title":"Horm Res"},{"issue":"suppl 7","key":"R40-16-20210212","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1471-0528.1992.tb13536.x","article-title":"Goserelin (Zoladex) in the treatment of fibroids.","volume":"99","author":"West","year":"1992","journal-title":"Br J Obstet Gynaecol"},{"key":"R41-16-20210212","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1471-0528.1989.tb01663.x","article-title":"Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.","volume":"96","author":"Matta","year":"1989","journal-title":"Br J Obstet Gynaecol"}],"container-title":["Obstetrical & Gynecological Survey"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/OGX.0000000000000036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:23:46Z","timestamp":1620966226000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006254-201402000-00016"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ogx.0000000000000036","relation":{},"ISSN":["0029-7828"],"issn-type":[{"value":"0029-7828","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}